How genetics is helping us understand Parkinson #39;s disease
The last twenty years have seen huge advances in our understanding of human genetics. In this webinar, I #39;ll talk about how looking at genetics is helping us to learn more about what causes...

By: Patrick Lewis

See the article here:
How genetics is helping us understand Parkinson's disease - Video

Recommendation and review posted by Bethany Smith

Let #39;s Play Die Sims 3 #008 Babies und Winterspa // Perfect Genetics Challenge
Perfect Genetics Challenge mit Elise Burelli. Mehr ber die Perfect Genetics Challenge erfahren: http://modthesims.info/t/454886 Mein Blog mit Geschichten zu Spielen und anderem: http://fa...

By: Fabulas Fiction

Read more here:
Let's Play Die Sims 3 #008 Babies und Winterspa // Perfect Genetics Challenge - Video

Recommendation and review posted by Bethany Smith

CHOP gene therapy expert fine-tunes protein signals, improves motor function and reduces brain shrinkage in a neurological disorder

IMAGE:Beverly L. Davidson, Ph.D., a gene therapy expert, is the director of The Center for Cellular and Molecular Therapeutics at the Children's Hospital of Philadelphia. view more

Credit: The Children's Hospital of Philadelphia

By adjusting the levels of a key signaling protein, researchers improved motor function and brain abnormalities in experimental animals with a form of Huntington's disease, a severe neurodegenerative disorder. The new findings may lay the groundwork of a novel treatment for people with this fatal, progressive disease.

"This research shows the intricate workings of a biological pathway crucial to the development of Huntington's disease, and is highly relevant to drug development," said study leader Beverly L. Davidson, Ph.D., director of The Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia (CHOP). "Our results in animals open the door to a promising potential therapy, based on carefully manipulating the dysregulated pathway to treat this devastating human disease."

She added that restoring proper balance to these delicate biological processes may offer even broader benefits in treating other neurological diseases, such as amyotrophic lateral sclerosis (ALS), fragile X mental retardation and autism.

The study team published its results online Dec. 31 in the journal Neuron.

Huntington's disease is an incurable, inherited disease entailing progressive loss of brain cells and motor function, usually beginning in midlife. A defective gene produces repeated copies of a protein called huntingtin, or HTT. The mutant HTT protein (mHTT) particularly damages a brain region called the striatum, where it interferes with normal cell growth and other fundamental biological events. The resulting disease includes involuntary movements and severe cognitive and emotional disturbances. About 30,000 Americans have Huntington's disease (HD).

Neuroscientists already knew that a signaling protein called mTORC1 that regulates cell growth and metabolism plays a major role in HD. Many researchers have proposed that inhibiting or shutting off the mTORC1 pathway, which interacts with the deleterious mHTT proteins, could help treat HD.

The current study contradicts those assumptions. "We show that the mTORC1 pathway is already impaired in Huntington's disease, and that improving how the pathway functions actually has a protective effect," said Davidson. "However, restoring that pathway must be done very carefully to avoid further harm. It's a 'Goldilocks effect.' You need to restore the mTORC1 level; either too much or too little is detrimental."

Read the original post:
Animal study points to a treatment for Huntington's disease

Recommendation and review posted by Bethany Smith

Stem cell treatment for Multiple Sclerosis - Case study
Mr. Scott recover after his suffer from MS for over 10 years. Puhua International Hospital provide stem cell treatment for neurological and neurosurgical disorders. http://www.puhuachina.com.

By: Puhua Hospital

See the original post here:
Stem cell treatment for Multiple Sclerosis - Case study - Video

Recommendation and review posted by simmons

Seal Beach, Laguna Hills, and Lake Forest, California (PRWEB) January 05, 2015

The Irvine Stem Cell Treatment Center announces a series of free public seminars on the use of adult stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief.

The seminars will be held on Sunday, January 11, 2015, at 2:30pm and 4:30pm at Marie Callenders Grill, 12489 Seal Beach Blvd., Seal Beach, CA 90740; Tuesday, January 13, 2015, at 2:00pm and 4:00pm at Pollys Pies, 23701 Moulton Parkway, Laguna Hills, CA 92653; Friday, January 16, 2015, at 1:30pm and 3:30pm at Marie Callenders Grill, 12489 Seal Beach Blvd., Seal Beach, CA 90740; Saturday, January 17, 2015, at 2:30pm and 4:30pm at Dennys Restaurant, 23515 El Toro Road, Lake Forest, CA 92630. Please RSVP at (949) 679-3889.

The Irvine Stem Cell Treatment Center, along with sister affiliates, the Miami Stem Cell Treatment Center and the Manhattan Regenerative Medicine Medical Group, abide by investigational protocols using adult adipose derived stem cells (ADSCs) which can be deployed to improve patients quality of life for a number of chronic, degenerative and inflammatory conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (found within a cellular mixture called stromal vascular fraction (SVF)). ADSCs are exceptionally abundant in adipose tissue. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly adult autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the body's natural healing cells - they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys injured cells. The Irvine Stem Cell Treatment Center only uses Adult Autologous Stem Cells from a persons own fat No embryonic stem cells are used. Current areas of study include: Emphysema, COPD, Asthma, Heart Failure, Parkinsons Disease, Stroke, Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Crohns Disease, and degenerative orthopedic joint conditions. For more information, or if someone thinks they may be a candidate for one of the adult stem cell protocols offered by the Irvine Stem Cell Treatment Center, they may contact Dr. Gionis directly at (949) 679-3889, or see a complete list of the Centers study areas at: http://www.IrvineStemCellsUSA.com.

About the Irvine Stem Cell Treatment Center: The Irvine Stem Cell Treatment Center, along with sister affiliates, the Miami Stem Cell Treatment Center and the Manhattan Regenerative Medicine Medical Group, is an affiliate of the Cell Surgical Network (CSN); we are located in Irvine and Westlake, California. We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Irvine Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Health, Office of Human Research Protection; and the study is registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information, visit our websites: http://www.IrvineStemCellsUSA.com, http://www.MiamiStemCellsUSA.com or http://www.NYStemCellsUSA.com.

See the original post here:
The Irvine Stem Cell Treatment Center Announces Adult Stem Cell Public Seminars in Orange County, California

Recommendation and review posted by simmons

Turning 10 years old may not quite mark adolescence for a human child, but for a major government research effort such as California's stem cell program, it's well past middle age.

So it's a little strange to hear C. Randal Mills, the new president and chief executive of the program known formally as the California Institute for Regenerative Medicine, say it's time to instill in CIRM "a clear sense of mission."

But that's what Mills is planning for the coming year, as he launches CIRM 2.0, a comprehensive reboot of the program.

Mills, a former biotech company chief executive, took over as CIRM's president last May. His first task, he told me, was to "take a step back and look broadly at how we do our business." He reached the conclusion that "there was a lot of room for improvement."

That's a striking admission for a program that already has allocated roughly two-thirds of its original $3-billion endowment.

Biomedical researchers are sure to find a lot to like about CIRM 2.0, especially Mills' commitment to streamline the program's grant and loan approval process for projects aimed at clinical trials of potential therapies. Reviews of applications take about 22 months on average; Mills hopes to cut that to about three months. The process can be made more efficient without sacrificing science: "We need to do it quickly and also focus on quality," he says in a videotaped presentation on the CIRM website. The CIRM board last month approved a six-month, $50-million round of funding under the new system, all to be aimed at testing new therapies.

Yet the focus on drug development shows that CIRM remains a prisoner of the politics that brought it into existence. The Proposition 71 campaign in 2004 employed inflated promises of cures for Parkinson's disease, Alzheimer's, diabetes and other therapy-resistant conditions to goad California voters into approving the $3-billion bond issue ($6 billion with interest) for stem cell research.

CIRM says it has funded clinical trials of 10 therapies and has backed an additional 87 projects "in the later stages of moving toward clinical trials." In scientific terms that's progress, but it may fall short of the public expectations of "cures" stoked by the initiative's promoters 10 years ago.

And that poses a political problem. At its current rate of grant and loan approvals of about $190 million a year, CIRM has enough funding to last until 2020. What happens after that is an open question, but any campaign to seek new public funding may depend on CIRM's having a successful therapy to show off to voters.

Mills says winning approval for more public funding isn't the goal of CIRM 2.0. "It's not our job at CIRM to extend the life of CIRM," he told me. Instead, he couches the need for urgency in terms of serving patients. As chief executive of Maryland-based Osiris Therapeutics, where he worked before joining CIRM, he says, he had "a firsthand view into the significance of stem cell treatment, and of how important urgency is in this game." Osiris received approval from the Food and Drug Administration and Canadian regulators for a stem cell drug to treat children with severe complications from bone marrow and other blood transplants.

Original post:
Ten years in, California's stem cell program is getting a reboot

Recommendation and review posted by simmons

Mayo Clinic #39;s Dr. Shane Shapiro Discussing Latest in Stem Cell Research at #WSCS14
Dr. Shane Shapiro, orthopedic physician, discussing highlights of stem cell research and regenerative medicine from the Mayo Clinic in Florida campus, during...

By: Mayo Clinic

Excerpt from:
Mayo Clinic's Dr. Shane Shapiro Discussing Latest in Stem Cell Research at #WSCS14 - Video

Recommendation and review posted by sam

Contact Information

Available for logged-in reporters only

Newswise Researchers Recreate Stem Cells From Deceased Patients to Study Present-Day Illnesses Cedars-Sinai research scientists have developed a novel method to re-create brain and intestinal stem cells from patients who died decades ago, using DNA from stored blood samples to study the potential causes of debilitating illnesses such as inflammatory bowel disease. The lab research, published in the journal STEM CELLS Translational Medicine, could yield new therapies for people who suffer from aggressive motor-neuron and gut-related conditions that proved fatal to the deceased patients who long-ago volunteered their blood samples. CONTACT: Cara Martinez, 310-423-7798; Email cara.martinez@cshs.org

Cedars-Sinai Heart Institute Physician-Researcher Awarded National Heart, Lung, and Blood Institute Grant to Develop Prevention Strategies for Deadly Heart Condition One of medicines most prominent experts in sudden cardiac arrest has received a new $2.36 million grant to study how to better predict the deadly heart condition that kills an estimated 300,000 Americans each year. Over recent years, Sumeet S. Chugh, MD, and his team of researchers in the Cedars-Sinai Heart Institute have identified several risk factors for sudden cardiac arrest, including levels of sex hormones in the blood, genetics and electrical and structural abnormalities of the heart. CONTACT: Sally Stewart, 310-248-6566; Email sally.stewart@cshs.org

Study Shows More Patients With Lou Gehrigs Disease Have Genetic Origin Than Previously Thought Genetics may play a larger role in causing Lou Gehrigs disease than previously believed, potentially accounting for more than one-third of all cases, according to one of the most comprehensive genetic studies to date of patients who suffer from the condition also known as amyotrophic lateral sclerosis, or ALS. The study, conducted by investigators at Cedars-Sinai and Washington University in St. Louis, also showed that patients with defects in two or more ALS-associated genes experience disease onset about 10 years earlier than patients with single-gene mutations. CONTACT: Sandy Van, 808-526-1708; Email sandy@prpacific.com

Computer System More Effective Than Doctors at Producing Comprehensive Patient Reports A computer system was more effective than doctors at collecting information about patient symptoms, producing reports that were more complete, organized and useful than narratives generated by physicians during office visits, according to a Cedars-Sinai study. Investigators said the research, published in the American Journal of Gastroenterology, highlights the potential of computers to enhance the quality of medical care and improve outcomes by harnessing accurate and thorough patient information. CONTACT: Duke Helfand, 310-248-6608; Email: duke.helfand@cshs.org

Double Lung Transplant Patient Pays Tribute to Donors Family in the Rose Parade Hours before receiving a lung transplant he thought would never happen, Michael Adams told his surgical team at Cedars-Sinai that hed be happy to live just one more year. Adams, 51, had suffered from cystic fibrosis since he was a baby. Hed been in and out of hospitals for as long as he could remember. By Thanksgiving of 2002, the former wheelchair company worker had end-stage disease. His lungs barely worked. Even eight liters of oxygen left him gasping for air. Then Adams received the call that saved his life: Two healthy lungs had suddenly become available. They belonged to a 15-year-old boy who had been shot and killed on the steps of his church 78 miles away in San Bernardino. Adams was transferred immediately to Cedars-Sinai, where he underwent a double lung transplant. He and his transplant surgeons are available for interviews CONTACT: Laura Coverson, 310-423-5215 Email: laura.coverson@cshs.org

# # #

Go here to see the original:
Cedars-Sinai Medical Tip Sheet for Jan., 2015

Recommendation and review posted by Bethany Smith

TUCSON Dr. Zain Khalpey stands next to a ghostly white lung pumping rhythmically on the table next to him. Thats pretty damn good, actually, Khalpey says as he gazes at the data recorded by the lungs ventilator.

The ventilator indicates that the pig lung is inflating and deflating like a normal lung. Experiments such as this bring research a step closer to the operating room.

Khalpey, an associate professor of surgery at the University of Arizona, focuses his research on making more organs available to patients who need a transplant. Every day, 18 people on organ transplant lists die, according to the U.S. Department of Health and Human Services.

In Arizona patients have to wait two to three years for a lung transplant, according to the U.S. National Library of Medicine. This waiting period is emotionally and financially draining for patients.

Khalpey is trying to shrink the wait time. He is taking damaged organs and refurbishing them so they end up in a needy patients body. Other organs too damaged to be refurbished are stripped of their cells and used to grow new organs with the patients stem cells.

In the future, donor organs may not even be needed. Khalpey is working on hybrid organs that are 3-D printed and then seeded with the patients stem cells.

From London

to Tucson

Khalpeys passion for transplant surgery started on a rainy day in 1990s London. A 16-year-old boy lay on the operating table about to undergo a heart-and-lung transplant. Cystic fibrosis caused his lungs to become a breeding ground for infection that whittled away his ability to breathe.

A team of surgeons replaced the boys lungs as well as his heart because he was more likely to survive with donor organs. The medical team rushed the boys viable heart to a second operating room, where it gave new life to another patient.

More:
Research looks to build organ stockpiles

Recommendation and review posted by Bethany Smith

January 4, 2015 4:00 AM

FILE (Credit: Thinkstock)

If youve listened to radio in the Delaware Valley, the odds are...

CBS Philly (con't)

Affordable Care Act Updates: CBSPhilly.com/ACA

Health News & Information: CBSPhilly.com/Health

By Lynne Adkins

PHILADELPHIA (CBS) Anationwide study Temple University is taking part inis for people who have no other treatment options available and their heart is failing.

Dr. Jon George, an interventional cardiologist at Temple University Hospital, says stem cells will be taken from the patients hip.

Were able to use these cells from the bone marrow to isolate the stem cell that are capable of regenerating the heat muscle and then inject them directly into the heart muscle where its needed.

Original post:
Temple University Taking Part In Study That Uses Stem Cells To Help Patients With End Stage Heart Failure

Recommendation and review posted by Bethany Smith

Pfizer Inc. (NYSE:PFE) announced today two strategic decisions to expand the companys rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients. First is an agreement with Spark Therapeutics to develop SPK-FIX, a program incorporating a bio-engineered AAV vector for the potential treatment of Hemophilia B expected to enter Phase 1/2 clinical trials in the first half of 2015. Additionally, Pfizer has appointed Michael Linden, Ph.D., Professor at Kings College London and Director of the University College London Gene Therapy Consortium, who will be with the company for a two-year secondment to lead gene therapy research in the rare disease area.

The fundamental understanding of the biology of hereditary rare diseases, coupled with advances in the technology to harness disarmed viruses as gene delivery vehicles, provide a ripe opportunity to investigate the next wave of potential life-changing therapies for patients, said Mikael Dolsten, M.D., Ph.D., president of Worldwide Research and Development at Pfizer. By establishing our gene therapy capabilities, we hope to gain a deeper understanding of the mechanisms that could potentially bring true disease modification for those suffering from devastating hematologic and neuromuscular diseases.

Agreement with Spark Therapeutics for Hemophilia Research

Philadelphia-based Spark Therapeutics and Pfizer will collaborate to progress the clinical program for SPK-FIX, a program incorporating a bio-engineered AAV vector for the potential treatment of hemophilia B. Pfizer has a long-standing commitment to the hemophilia community and has been providing hemophilia products to patients for more than 17 years.

Pfizer strives to provide meaningful enhancements to the lives of patients with hemophilia, and the agreement with Spark Therapeutics offers an important expansion of Pfizers commitment to the bleeding disorder community and builds on our leading hemophilia portfolio, said Geno Germano, group president, Global Innovative Pharma Business at Pfizer. We believe the SPK-FIX program could add to our existing portfolio of hemophilia products and could pioneer a potential new treatment technology for patients with bleeding disorders.

Under the terms of the agreement, Spark will maintain responsibility for clinical development through Phase 1/2 studies. Pfizer will assume responsibility for pivotal studies, any regulatory approvals and potential global commercialization of the product.

Establishment of Gene Therapy Research in Pfizer Rare Disease

Effective December 1, 2014, Professor Michael Linden has joined Pfizer from his current position at Kings College London, for a two-year secondment to lead gene therapy research within the companys rare disease research area.

The establishment of a gene therapy group under the leadership of Professor Linden will help Pfizer explore the potential of this important technology that could possibly benefit patients living with serious diseases, said Kevin Lee, Ph.D., senior vice president and chief scientific officer of Pfizers Rare Disease Research Unit. Professor Linden brings to Pfizer his extensive expertise in AAV technology obtained from over 20 years working in the field.

Pfizer and Rare Diseases

Read this article:
Pfizer Expands Rare Disease Research with Establishment of ...

Recommendation and review posted by Bethany Smith

summary

We are investigating possible ways of treating genetic disorders. One method involves gene therapy - introducing 'healthy' copies of genes into a patient's cells. This concept has proved harder to implement than previously thought. For example, the large size of most human genes has necessitated the use of 'stripped-down' versions of these genes. However, minimising the amount of genetic material used can exclude stretches of DNA that would normally control the gene's function.

Safer and more efficient ways of delivering these 'replacement' genes directly to their target cells need to be devised. Research is also required on how to keep the inserted DNA intact and retain its normal functions in the cell. We are very aware of the serious concerns about the safety and effectiveness of gene therapy, and are committed to addressing these issues.

We are also investigating treatments based on cell therapy, and the use of drugs to modify gene expression. In many genetic illnesses, it may even be possible to alter other genes pharmacologically so as to overcome the disease.

Dr Jim Vadolas Cell & Gene Therapy Murdoch Childrens Research Institute Royal Children's Hospital Flemington Road Parkville Victoria 3052 Australia

T +61 3 8341 6232 (Office) T +61 3 8341 6236 (Lab) F +61 3 9348 1391 E jim.vadolas@mcri.edu.au

Group Leader Biography

Dr Jim Vadolas completed his PhD at the Departments of Microbiology and Immunology, University of Melbourne, and postdoctoral training at the Murdoch Childrens Research Institutewith Panos Ioannou and Bob Williamson. In 2005, Jim became group leader of the Cell and Gene Therapy group at the MCRI.He is primarily interested in the development ofnew therapeutic strategies for thalassaemia and related haemoglobinopathies. His work has led the establishment of several new model systems that can be used to identify and evaluate potential therapies. He is currently an Executive Committee member of the Australasian Gene Therapy Society. Jim is also an Executive Committee Member of Thalassaemia Australia.

Project 1: Development of RNAi therapy for thalassaemia

-Thalassaemia is an inherited disease caused by defective synthesis of the -globin chain of haemoglobin, leading to imbalanced globin chains. Excess -chains precipitate in erythroid progenitor cells resulting in cell death, ineffective erythropoiesis and severe anaemia. Decreased -globin chain synthesis leads to milder symptoms, exemplified by individuals who co-inherit -thalassaemia and -thalassaemia. Therefore, a possible therapeutic strategy in the treatment of -thalassaemia could include targeted reduction of -globin chains to mimic co-inheritance of /-thalassaemia. One way of reducing -chain synthesis is by using RNA interfering (RNAi). Numerous studies have shown promising results utilising RNAi in vitro and in vivo. This study will investigate the use of RNAi-mediated reduction of -globin chains for the therapy for -thalassaemia.

Originally posted here:
Murdoch Childrens Research Institute : cell & gene therapy

Recommendation and review posted by Bethany Smith

Doug Whitney has showed no signs of early onset Alzheimers despite having a mutated gene that puts him at high risk of contracting the disease. Photo: Matthew Ryan Williams

Doug Whitney should have died years ago. The 65-year-old resident of Port Orchard, Washington, has a devastating gene mutation that, according to the medical literature, causes early-onset Alzheimer's disease in everyone who inherits it.

The mutation killed Whitney's mother and nine of her 13 siblings, and it killed Whitney's older brother. Every one of them began showing symptoms when they were in their 40s. Most died by their mid-50s.

In the next generation, six cousins died of early-onset Alzheimer's and two others are in the final stages of the disease. One of Whitney's cousin's children also has Alzheimer's.

But Whitney has somehow escaped that fate. His memory is intact and he has no signs of Alzheimer's disease. Researchers want to find out why. They suspect he has another gene mutation that somehow protects him from the horrific Alzheimer's gene mutation or that, at least, substantially delays the disease's onset.

Advertisement

So Whitney has become exhibit A in a new direction in genetics research. After years of looking for mutations that cause diseases, investigators are now searching for those that prevent them. By understanding how protective mutations work, they hope to develop drugs that mimic them and protect everyone.

The new approach was turning genetics research on its head, said Dr Eric Schadt, director of the Icahn Institute, a medical research institute at Mount Sinai in New York.

"Instead of trying to fix things that are broken, let's look at people where things are broken but nature finds a way around it," he said.

In recent years, a few astounding protective gene mutations have been discovered, pretty much by accident. One prevents HIV from entering cells and another enormously reduces the amount of LDL cholesterol, the dangerous kind, that people make. Both led to drugs. The AIDS drug is a mainstay of treatment, and the cholesterol drug is in the final stages of testing.

Continue reading here:
Scientists hope man with killer mutant gene who refuses to die will provide clues to cure disease

Recommendation and review posted by Bethany Smith

The Dark Trilogy - Episode 15 "Genetic Engineering"
A modded minecraft Let #39;s Play series featuring The Dark Trilogy modpack available on the Feed the Beast launcher in the 3rd party modpacks section. This worl...

By: hossumquat

Read more from the original source:
The Dark Trilogy - Episode 15 "Genetic Engineering" - Video

Recommendation and review posted by Bethany Smith

Automotive engineering is a branch of engineering that studies how to design, create and develop the means of land transportation are using the machine, especially motorcycles, cars, buses and trucks. Automotive engineering combines elements of knowledge of mechanics, electricity, electronics, safety and the environment as well as mathematics, physics, chemistry, biology and management.The branches of the automotive engineering include:Planning (product or design)Development (development)Production (manufacturing)Maintenance (maintenance)In Indonesia currently highly developed branch is generally about care and maintenance of cars and motorcycles.In automotive engineering, control systems existing land transport equipment is a must. The system comprises several main systems and dozens of subsystems. The system can be grouped:Engine (engine)Combustion engine (internal combustion engine).The fuel system (fuel system).Fuel tank.Fuel pump.Carburetor or fuel injection system.Ignition system (ignition system).Air intake system in the combustion chamber (intake system).Combustion products exhaust system (exhaust system).Cooling system (cooling system).Lubrication system (lubricating system).Wheel balance system (spooring balancing)Move power (power train).Transmission system (transmission system).Driving circuit (drive train).Transfer case (for 4-wheel drive)The driving end (final drive)Wheel (wheel)The steering system (steering system).The suspension system (suspension system).The brake system (brake system).Bodi.The electrical system (electrical system).The main fields of technologyfieldBuilding and ConstructionCity and Regional Planning Techniques Acoustic Engineering Mechanical Engineering Safety Engineering architecture building maintenance engineering construction fire protection engineering Civil engineering Sanitation Engineering Technology household structurebiomedicalBiomechatronics Bioinformatics Biotechnology Pharmacology Nanomedicine Science Health Sciences Informatics nerve chemical Medical Research Biomedical Engineering Biological Engineering Genetic Engineering Medical Technology Network Engineering Technology Reproductive Technology nerveenergyRenewable Energy Storage Petroleum Engineering Nuclear Engineering Energy Nuclear TechnologyindustryGas industrial biotechnology industry Metallurgy Research Management Manufacturing techniques and the development of flexible manufacturing systems Biochemical engineering Biosystems engineering Financial engineering industry Mechanical Engineering Manufacturing Engineering Enterprise engineering Mining Engineering Engineering process automationInformation and CommunicationArtificial intelligence Computer Science Mechanical Engineering radio frequency and computer engineering computer network ontology Mechanical Engineering Software Engineering broadcasting telecommunication Engineering Engineering Technology website computing technology information technology communication technology visual music Graphic TechnologyenvironmentGreen building design of ecologically sustainable design Renewable energy Science Engineering Environmental engineering environment landscape clean coal technology clean technology Green nanotechnologymilitaryElectronic warfare military communications military engineering stealth Technology EngineerseducationDigital Technology educational software in educational ICT in education Impact of technology in the education system of multimedia learning Virtual Campus Virtual EducationagricultureAquaculture fishery Sciences Chemistry Environmental food and agricultural buildings Nutrition Food Microbiology Food Engineering Agricultural Engineering Technology Food Technology freezing foodtransportationAerospace engineering Traffic Engineering Mechanical Engineering Automotive Engineering shipping space transportation technologyOther applied sciencesContent rating: Medium Maturity

Here is the original post:
Automotive Reference

Recommendation and review posted by Bethany Smith

Update lady sativa genetics
Knightsbridge og x haze so far no issues besides that it does some stretching in flowering. Keep medicating!!!!!!

By: (RMC)rockymountaincultivators

Follow this link:
Update lady sativa genetics - Video

Recommendation and review posted by Bethany Smith

Lets Play The Sims 3 Perfect Genetics/100 Baby Challenge Part 3: Whohooing Time!
DONATIONS (Optional): ...

By: GBabyChallenger

Here is the original post:
Lets Play The Sims 3 Perfect Genetics/100 Baby Challenge Part 3: Whohooing Time! - Video

Recommendation and review posted by Bethany Smith

Bodybuilding Motivation 2015 - Genetics
World Leading Gym Apparel http://www.PhysiqApparel.com | Use code #39;SLAVS10 #39; for 10% off Chek out Beast Motivation : http://beastmotivation.com/ Facebook page: ...

By: slavvs

Continue reading here:
Bodybuilding Motivation 2015 - Genetics - Video

Recommendation and review posted by Bethany Smith

CF Unite: CF Genes Genetics.
Dr Ian Pringle discusses CF genes and how new technology is speeding up research and discovery. He also talks candidly about the day the gene sequence for the CFTR mutation changed ever so...

By: ukcfgtc

More here:
CF Unite: CF Genes & Genetics. - Video

Recommendation and review posted by Bethany Smith

Spinal Cord Injury Standing at NeuroFit360
Spinal Cord Injury client re-learned how to use his leg muscles to stand again after yeasrs post injury.

By: Guy Romain

Visit link:
Spinal Cord Injury Standing at NeuroFit360 - Video

Recommendation and review posted by sam

Mayo Clinic #39;s Dr. Rick Hayden Discussing Regenerative Medicine Education at #WSCS14
Mayo Clinic #39;s Dr. Rick Hayden, director of education for the Mayo Clinic Center for Regenerative Medicine, discussing the importance of regenerative medicine...

By: Mayo Clinic

See the original post here:
Mayo Clinic's Dr. Rick Hayden Discussing Regenerative Medicine Education at #WSCS14 - Video

Recommendation and review posted by sam

NEW YORK ( TheStreet) -- Shares of Brainstorm Cell Therapeutics (BCLI) surged more than 75% to a 52-week high of $8.47 on Fridayahead of the biotech company's data release on Monday.

Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn. The company describes NurOwn as an "autologous, adult stem cell therapy technology" designed to treat ALS, also known as Lou Gehrig's Disease.

The company will host a conference call on Monday to discuss the results.

Exclusive Report: Jim Cramer's Best Stocks for 2015

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

The rest is here:
Brainstorm Cell Therapeutics (BCLI) Stock Hits One-Year High Today

Recommendation and review posted by simmons

NEW YORK (TheStreet) -- Shares ofNeuralstem (CUR) continue to rise, up 6.25% to $2.89, in morning trading Friday in sympathy with peer company Brainstorm Cell Therapeutics (BCLI) , which touched a one-year high on Friday.

Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn on Monday. The company describes NurOwn as an "autologous, adult stem cell therapy technology" designed to treat ALS, also known as Lou Gehrig's Disease.

The company will host a conference call on Monday to discuss the results.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

See the article here:
Neuralstem (CUR) Stock Rises Today as Brainstorm Cell Therapeutics Soars

Recommendation and review posted by simmons

Stem cells are very early blood cells. They are normally found in the bone marrow. Doctors use growth factor injections to make some of them move into the bloodstream. This makes it easier to collect them. You have growth factors as an injection just under the skin, usually in your tummy (abdomen), or into an arm or a leg. You have these once a day, for up to 10 days at a time and can learn to give them yourself at home.

Growth factor injections can cause itching around the injection site. You may have some aching in your bones after you have had a few injections. This is because there are a lot of blood cells being made inside the bones. The aching is usually easy to control with a mild painkiller, such as paracetamol. The pain will go away after a day or so.

After your course of injections, you will have regular blood tests to see how many stem cells are in your blood. When there are enough, you will have them collected. Collecting stem cells takes 3 or 4 hours. You sit in a chair or lie down on a couch and have a fine tube put into a vein in each of your arms. The nurse attaches these to a machine called a stem cell separator. Your blood passes out of one drip, through the machine and back into your body through the other drip. The machine filters the stem cells out of your blood but gives you the rest of the cells and the plasma back. The donor stem cells are frozen and stored. Most donors need to have another collection the following day, to make sure there are enough cells.

View post:
Bone marrow and stem cell transplants for chronic myeloid ...

Recommendation and review posted by Bethany Smith

January 2, 2015

Credit: Thinkstock

Chuck Bednar for redOrbit.com Your Universe Online

Fat cells located beneath a persons skin could help protect them from bacterial infections, according to a new study published Thursday in the journal Science.

In the study, Dr. Richard Gallo, a professor and chief of dermatology at the University of California, San Diego School of Medicine, and his colleagues report that they had discovered a previously unknown function of these dermal fat cells, also known as adipocytes: they produce antimicrobial peptides that help combat bacteria and other types of pathogens.

It was thought that once the skin barrier was broken, it was entirely the responsibility of circulating (white) blood cells like neutrophils and macrophages to protect us from getting sepsis, explained Gallo. But it takes time to recruit these cells (to the wound site).

We now show that the fat stem cells are responsible for protecting us. That was totally unexpected, he added. It was not known that adipocytes could produce antimicrobials, let alone that they make almost as much as a neutrophil.

A persons body launches a complex, multi-tiered defense against microbial infection, the authors said. Several different types of cells are involved, and the process ends with the arrival of specialized cells known as neutrophils and monocytes that target and destroy pathogens.

Before any of that can happen, a more immediate response is required one that can counter the ability of pathogens to rapidly increase their numbers, however. That task is typically performed by epithelial cells, mast cells and leukocytes residing in the area of infection.

Previous research conducted in Gallos lab detected Staphylococcus aureus, a common type of bacteria and a major source of skin infection on humans, in the fat layer of the skin. Antibiotic-resistant forms of this bacterial have become a significant health issue throughout the world, so the study authors looked to see what role adipocytes played in preventing skin infections.

The rest is here:
Fat cells may actually not be so bad

Recommendation and review posted by Bethany Smith